Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

NCT05768347 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Non-Invasive Bladder Urothelial Carcinoma

Interventions

BIOLOGICAL: Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

United States Department of Defense